🟢 94/100

This product looks safe

  • Niacin: 100mg is 2.9× the Tolerable Upper Intake Level (35mg)
  • 83% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 100mg is 2.9× the Tolerable Upper Intake Level (35mg)

Label Data

1 Tablet(s) Serving Size
Other Combinations Product Type
83% Evidence Coverage

Supplement Facts — Evidence Check

100 mg (500% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 2.9× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 100mg UL 35mg
5 mg (250% DV)
📊 3.8× RDA — above typical dose (UL: 100 mg) 📚 113 studies (Tier A: 3, B: 35)
RDA 1.3mg This product: 5mg UL 100mg
📊 Market median: 550.0mg (217 products) 📚 29 studies (Tier A: 0, B: 5)
This product: 100mg
25 mg
✅ 1.8× RDA — within safe limits 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 25mg UL 35mg
Gamma Oryzanol
25 mg
📊 Market median: 300.0mg (122 products) 📚 22 studies (Tier A: 0, B: 7)
This product: 50mg

Label Claims — Verification

All Other
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years) Gluten Free Sugar Free

Product Information

📋 Directions for Use

Directions for use: One tablet daily, or as directed.

⚠️ Warnings & Precautions

SOME PEOPLE MAY EXPERIENCE SOME FLUSHING. DO NOT TAKE ON AN EMPTY STOMACH. CONTACT YOUR DOCTOR IF YOU HAVE ANY QUESTIONS.

KEEP OUT OF REACH OF CHILDREN.

TAMPER RESISTANT OUTER SEAL - DO NOT USE IF BROKEN.

🧪 Formulation Notes

Contains no starch, salt, sugar, corn, yeast, soy, gluten, or preservatives.

Additional Information

Product # 2745

Manufactured under strict GMP and USP guidelines.

"When You Want The Best"

MFG05/2009

FOR DISTRIBUTION BY HEALTH CARE PROFESSIONALS ONLY.

Store in cool, dry place.

Product Details

DSLD Entry Date 2013-12-24
Product Type Other Combinations
Form Tablet or Pill
Brand Nutri-West
DSLD ID 28631
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →